Oversight Committee of the Cancer Prevention and Research Institute of Texas Meeting Minutes
The committee reviewed reports from the CEO, Chief Scientific Officer, Chief Product Development Officer, and Chief Compliance Officer regarding grant award recommendations for academic research and product development programs. Key discussions included appointment approvals for various advisory committees, the adoption of an honoraria policy, the approval of health and safety code waivers, and proposed rule amendments. Additionally, the committee reviewed internal auditor reports, grant management platform modernization updates, and authorized the disbursement of grant funds via advance payments. Financial matters, including the operating budget, bond issuance resolutions, and legislative appropriations requests for the 2028-2029 biennium, were also addressed.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The committee meeting covered a wide range of administrative, compliance, and programmatic topics. These included CEO, compliance, scientific, and product development officer reports, alongside recommendations for academic research and product development grant awards. Discussions also encompassed the appointment of members to various advisory and scientific research committees, proposed amendments to administrative rules, financial status updates, legislative appropriation requests, and bond issuance resolutions. Additionally, the committee addressed internal audit reports, compliance training, and preparations for upcoming conferences.
Feb 18, 2026·Board meeting
Oversight Committee Meeting
Key discussions and actions during the meeting included a presentation from a CPRIT-funded grantee, Dr. Thanh Hoang, regarding her work on pediatric cancer epidemiology and susceptibility. The CEO presented a report covering FY 2026 grant funds, the 2025 Annual Report, and personnel matters. Reports were given by the Chief Compliance Officer on grantee reporting, financial reviews, and compliance certifications; the Chief Scientific Officer on Academic Research Program updates and recruitment award recommendations; and the Chief Prevention Officer on the Prevention Program. The Chief Product Development Officer presented on the Product Development Research Program and recommended four FY 2027 Requests for Applications (RFAs). The committee addressed appointments to the Scientific Research and Prevention Programs Committees and finalized provisional appointments to the Advisory Committees, including receiving annual reports from related advisory committees. Proposed amendments to 25 TAC Chapter 703 regarding administrative rules were presented for consideration. Financial reports covered the operating budget and debt issuance history. Updates were provided on planning for the CPRIT Innovations VII Conference and general communications efforts. The committee also reviewed and approved the FY 2027 Program Priorities and received a report from the Geographic Diversity Advisory Committee concerning funding outreach to underserved areas.
